Belimumab
Childhood Acute Lymphoblastic Leukemia
Peking Union Medical College Hospitalmonoclonal_antibodyPhase 4 / ApprovedActive
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 81/ 100
Competitive context
64 Active assets in the Childhood Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vincristine Sulfate National Cancer Institute (NCI) | Phase 3 | BBB |
Methotrexate Children's Oncology Group | Phase 3 | BBB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 3 | BBB |
Cytarabine Children's Oncology Group | Phase 3 | BBB |
Nivestim St. Jude Children's Research Hospital | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Belimumab is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →